|
|
|
|
LEADER |
00000cam a2200000Mu 4500 |
001 |
EBSCO_ocn990537291 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr |n|---||||| |
008 |
131209s2013 enk ob 001 0 eng d |
040 |
|
|
|a LIP
|b eng
|e pn
|c LIP
|d OCLCO
|d N$T
|d YDXCP
|d EBLCP
|d IDEBK
|d E7B
|d MHW
|d CDX
|d DEBSZ
|d OCLCF
|d CUV
|d KIJ
|d STBDS
|d LGG
|d OCLCQ
|d NJR
|d OCLCO
|d OCL
|d OCLCA
|d OCLCQ
|d K6U
|d OCLCQ
|d UKAHL
|d QGK
|d OCLCO
|d OCLCQ
|d OCL
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 854854023
|a 1241962583
|a 1264959609
|
020 |
|
|
|a 0199609144
|
020 |
|
|
|a 9780199609147
|
020 |
|
|
|a 1299753272
|
020 |
|
|
|a 9781299753273
|
020 |
|
|
|a 9780191510397
|
020 |
|
|
|a 0191510394
|
020 |
|
|
|a 0191742775
|
020 |
|
|
|a 9780191742774
|
029 |
1 |
|
|a AU@
|b 000055905091
|
029 |
1 |
|
|a AU@
|b 000062594220
|
029 |
1 |
|
|a DEBSZ
|b 39286939X
|
035 |
|
|
|a (OCoLC)990537291
|z (OCoLC)854854023
|z (OCoLC)1241962583
|z (OCoLC)1264959609
|
037 |
|
|
|a 506578
|b MIL
|
050 |
|
4 |
|a RS122.95 .K384 2013
|
072 |
|
7 |
|a MED
|x 023000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 058170
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 072000
|2 bisacsh
|
082 |
0 |
4 |
|a 615.1
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Kilcoyne, Adrian.
|
245 |
1 |
0 |
|a Pharmaceutical Medicine.
|
246 |
3 |
|
|a Oxford Specialist Handbooks
|
264 |
|
1 |
|a [Oxford] :
|b Oxford University Press,
|c 2013.
|
300 |
|
|
|a 1 online resource (473 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Oxford Specialist Handbooks
|
588 |
0 |
|
|a Print version record.
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Cover; Contents; Preface; Contributors; Abbreviations; Section 1: Discovery of new medicines; 1.1 Intellectual property in discovery; 1.2 Targeted drug discovery: receptor-based approaches; 1.3 In vitro and in vivo testing of new compounds; 1.4 Lead optimization; 1.5 Natural products and herbal medicines; Section 2: Medicines regulation; 2.1 General principles of medicines regulation; 2.2 Medicines regulation in the UK; 2.3 Medicines regulation in the EU; 2.4 The European Medicines Agency and Heads of Medicines Agencies.
|
505 |
8 |
|
|a 2.5 The European Directorate for the Quality of Medicines and HealthCare, European Pharmacopoeia, and British Pharmacopoeia2.6 The Food and Drug Administration; 2.7 Health Canada; 2.8 Medsafe and the Therapeutic Goods Administration; 2.9 Medicines regulation in Japan; 2.10 Medicines regulation in China; 2.11 Medical device regulation; 2.12 Clinical trials regulation; 2.13 Good clinical practice; 2.14 Good laboratory practice and good clinical laboratory practice; 2.15 Good manufacturing practice; 2.16 The Ethics Committee (EU); 2.17 The Institutional Review Board (US).
|
505 |
8 |
|
|a 2.18 Marketing authorization applications and updating and maintaining licences2.19 The International Conference on Harmonisation; 2.20 Common technical document; 2.21 Medicinal product information in the European Union; 2.22 Summary of product characteristics; 2.23 Orphan drugs; 2.24 Paediatric investigational plans; 2.25 Regulatory requirements for pharmacovigilance; 2.26 Overview of reporting of adverse drug reactions; 2.27 Non-prescription drugs; 2.28 Provision of unlicensed medicines; 2.29 Reclassification of medicines; 2.30 Parallel imports; Section 3: Clinical pharmacology.
|
505 |
8 |
|
|a 3.1 Absorption, distribution, metabolism, and excretion3.2 Volume of distribution, clearance, half-life; 3.3 Pre-clinical aspects of pharmacokinetics; 3.4 Non-clinical data; 3.5 Clinical aspects of pharmacokinetics; 3.6 Dose-response relationship; 3.7 Proof of concept studies; 3.8 Reproductive toxicity studies; 3.9 Immunotoxicity testing; 3.10 Carcinogenicity; 3.11 Genotoxicity testing; 3.12 Local tolerance; 3.13 Acute toxicity; 3.14 Studies: objectives, design, conduct, and analysis; 3.15 Populations for exploratory studies and planning of exploratory studies; 3.16 Pharmacodynamic endpoints.
|
505 |
8 |
|
|a 3.17 Bioavailability and bioequivalence3.18 Evaluation of safety and tolerability; 3.19 Hypersensitivity reactions; 3.20 Drug-drug interactions; 3.21 Ethics in research: basic principles, Declaration of Helsinki, and Council for International Organizations of Medical Sciences; 3.22 Disease models; 3.23 Biomarkers; 3.24 Pharmacogenetics; 3.25 Population pharmacokinetics; 3.26 Small molecules and biologicals: safety and pharmacology requirements; Section 4: Clinical development; 4.1 Requirements for licensing a new medicinal product; 4.2 Regulatory guidance.
|
500 |
|
|
|a 4.3 General principles of clinical trial protocols.
|
520 |
|
|
|a The breadth of the pharmaceutical medicine can be daunting, but this book is designed to navigate a path through the speciality. Providing a broad overview of all topics relevant to the discipline of pharmaceutical medicine, it gives you the facts fast, in a user-friendly format, without having to dive through page upon page of dense text. With 136 chapters spread across 8 sections, the text offers a thorough grounding in issues ranging from medicines regulation to clinical trial design and data management. This makes it a useful revision aid for exams as well as giving you a taster of areas o.
|
546 |
|
|
|a English.
|
588 |
0 |
|
|a Online resource; title from home page (viewed on July 8, 2013).
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Clinical pharmacology.
|
650 |
|
0 |
|a Drug development.
|
650 |
|
0 |
|a Medical personnel.
|
650 |
|
0 |
|a Therapeutics.
|
650 |
|
0 |
|a Drugs.
|
650 |
|
0 |
|a Chemotherapy.
|
650 |
|
0 |
|a Pharmacy.
|
650 |
|
2 |
|a Chemicals and Drugs
|
650 |
|
2 |
|a Health Occupations
|
650 |
|
2 |
|a Therapeutics
|
650 |
|
2 |
|a Analytical, Diagnostic and Therapeutic Techniques and Equipment
|
650 |
|
2 |
|a Disciplines and Occupations
|
650 |
|
2 |
|a Pharmaceutical Preparations
|
650 |
|
2 |
|a Drug Therapy
|
650 |
|
2 |
|a Pharmacy
|
650 |
|
2 |
|a Pharmacology, Clinical
|
650 |
|
6 |
|a Pharmacologie clinique.
|
650 |
|
6 |
|a Médicaments
|x Développement.
|
650 |
|
6 |
|a Personnel médical.
|
650 |
|
6 |
|a Thérapeutique.
|
650 |
|
6 |
|a Médicaments.
|
650 |
|
6 |
|a Chimiothérapie.
|
650 |
|
6 |
|a Pharmacie.
|
650 |
|
7 |
|a pharmacies (health facilities )
|2 aat
|
650 |
|
7 |
|a treating (health care function)
|2 aat
|
650 |
|
7 |
|a pharmacy (discipline)
|2 aat
|
650 |
|
7 |
|a MEDICAL
|x Drug Guides.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Nursing
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Pharmacy.
|2 bisacsh
|
650 |
|
7 |
|a Therapeutics
|2 fast
|
650 |
|
7 |
|a Pharmacy
|2 fast
|
650 |
|
7 |
|a Medical personnel
|2 fast
|
650 |
|
7 |
|a Drugs
|2 fast
|
650 |
|
7 |
|a Chemotherapy
|2 fast
|
650 |
|
7 |
|a Clinical pharmacology
|2 fast
|
650 |
|
7 |
|a Drug development
|2 fast
|
700 |
1 |
|
|a Ambery, Phil.
|
700 |
1 |
|
|a O'Connor, Daniel.
|
776 |
0 |
8 |
|i Print version:
|t Pharmaceutical medicine
|z 9780199609147
|w (OCoLC)825557405
|
830 |
|
0 |
|a Oxford specialist handbooks.
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=615422
|z Texto completo
|
938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH25954560
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL7036301
|
938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH25954788
|
938 |
|
|
|a Coutts Information Services
|b COUT
|n 26007546
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL1336482
|
938 |
|
|
|a ebrary
|b EBRY
|n ebr10738623
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 615422
|
938 |
|
|
|a ProQuest MyiLibrary Digital eBook Collection
|b IDEB
|n cis26007546
|
938 |
|
|
|a Oxford University Press USA
|b OUPR
|n EDZ0000131200
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 10887198
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 12890131
|
994 |
|
|
|a 92
|b IZTAP
|